Author:
Rahman Khaliqur,Gupta Ruchi,Harankhedkar Shivangi,Gupta Tanvi,Sarkar Manoj K.,Nityanand Soniya
Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Nagarajan S, Brodsky RA, Young NS, Medof ME (1995) Genetic defects underlying paroxysmal nocturnal hemoglobinuria that arises out of aplastic anemia. Blood 86:4656–4661
2. Takahashi M, Takeda J, Hirose S, Hyman R, Inoue N, Miyata T et al (1993) Deficient biosynthesis of N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 177:517–521
3. Medof ME, Kinoshita T, Nussenzweig V (1984) Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 160:1558–1578
4. Rollins SA, Sims PJ (1990) The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 144:3478–3483
5. Borowitz MJ, Craig FE, DiGiuseppe J, Illingworth AJ, Rosse W, Sutherland R et al (2010) Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by Flow cytometry. Cytom B 78B:211–230